论文部分内容阅读
本文首次从正常大熊猫粪便中筛选出的乳杆菌菌株制成乳杆菌制剂，在进行了对小白鼠、家兔、家犬的急性毒性实验无毒性反应之基础上，对几例不同年龄、性别的患病大熊猫进行了临床应用。初步结果显示，该微生态制剂安全无毒副作用，对大熊猫腹泻、肠炎、营养不良等疾患疗效显著，填补了大熊猫无专用生物制剂的空白，为大熊猫消化系统疾病防治开辟了一条新的途径。
In this paper, Lactobacillus strains screened from normal panda’s feces for the first time were made into Lactobacillus preparations. Based on the non-toxic reaction of acute toxicity test to mice, rabbits and domestic dogs, The sick giant panda was used clinically. The preliminary results showed that the probiotics had no toxicity and side effects and had significant effects on diarrhea, enteritis and malnutrition in giant panda. It filled up the blank of pandas without any special biological agents and opened a new era for the prevention and treatment of panda digestive diseases way.